{"disease":{"id":"medullary-thyroid-cancer","name":"medullary thyroid cancer"},"drugs":{"marketed":[{"drug_id":"cabometyx","indication_name":"Progressive, Metastatic Medullary Thyroid Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cometriq","generic_name":"Cabometyx","company_name":"Exelixis","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor receptor 2","drug_class":"Kinase Inhibitor","quality_score":70,"revenue":"2200","mechanism":"Cometriq blocks the VEGFR2 pathway to prevent tumor growth and angiogenesis."},{"drug_id":"cabozantinib","indication_name":"Progressive, Metastatic Medullary Thyroid Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cometriq","generic_name":"CABOZANTINIB","company_name":"Exelixis Inc","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor receptor 2","drug_class":"Kinase Inhibitor","quality_score":53,"revenue":null,"mechanism":"Cometriq works by blocking the activity of vascular endothelial growth factor receptor 2, a protein involved in tumor growth and angiogenesis."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06523582","title":"Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients","phase":"","overall_status":"RECRUITING","enrollment_count":750,"lead_sponsor_name":"Universidad Nacional Autonoma de Mexico","has_results":false},{"nct_id":"NCT03037385","title":"Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":590,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT01109420","title":"Clinical and Genetic Studies in Familial Non-medullary Thyroid Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","has_results":false},{"nct_id":"NCT06292988","title":"Predictive Factors for Medullary Thyroid Cancer Aggressiveness","phase":"","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"Aristotle University Of Thessaloniki","has_results":false},{"nct_id":"NCT01660984","title":"Natural History Study of Children and Adults With Medullary Thyroid Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":259,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07259304","title":"Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT05675605","title":"A Study of TY-1091 in Patients With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":248,"lead_sponsor_name":"TYK Medicines, Inc","has_results":false},{"nct_id":"NCT06243965","title":"Is Desmoplastic Stromal Reaction Useful to Modulate Lymph Node Dissection in Sporadic Medullary Thyroid Carcinoma?","phase":"","overall_status":"COMPLETED","enrollment_count":246,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT01298323","title":"Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":205,"lead_sponsor_name":"Sanofi","has_results":true},{"nct_id":"NCT02709889","title":"Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":200,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT05278364","title":"Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":184,"lead_sponsor_name":"Shouyao Holdings (Beijing) Co. LTD","has_results":false},{"nct_id":"NCT04522570","title":"Thermal Ablation of Cervical Metastases From Thyroid Carcinoma","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":84,"lead_sponsor_name":"Instituto do Cancer do Estado de São Paulo","has_results":false},{"nct_id":"NCT03643055","title":"18F-Fluorocholine PET/CT in Medullary Thyroid Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"University Medical Centre Ljubljana","has_results":false},{"nct_id":"NCT06277180","title":"68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC","phase":"NA","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT04161391","title":"Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":41,"lead_sponsor_name":"Turning Point Therapeutics, Inc.","has_results":true},{"nct_id":"NCT07048964","title":"A Prospective Cohort Study of Pralsetinib or Anlotinib in the Treatment of Locally Advanced and/or Metastatic Medullary Thyroid Carcinoma With RET Gene Mutations","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT07142005","title":"Cultural Adaptation of an Educational Tool in Medullary Thyroid Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01856920","title":"QUILT-3.006 for Recurrent Medullary Thyroid Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"NantCell, Inc.","has_results":true},{"nct_id":"NCT01945762","title":"Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":false},{"nct_id":"NCT02856347","title":"Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin","phase":"NA","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Institut Claudius Regaud","has_results":false},{"nct_id":"NCT06141369","title":"Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)","phase":"NA","overall_status":"RECRUITING","enrollment_count":21,"lead_sponsor_name":"Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT04877613","title":"GFRα4 CAR T Cells in MTC Patients","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":18,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT03072160","title":"Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05534594","title":"Evaluation of the 18F-PSMA Positron Emission Tomography (PET)/CT in Patients With Medullary Thyroid Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"University Medical Center Groningen","has_results":false},{"nct_id":"NCT04514484","title":"Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":8,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03630120","title":"Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":true},{"nct_id":"NCT04760288","title":"A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).","phase":"PHASE3","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT03838692","title":"Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Antonio Fojo","has_results":false},{"nct_id":"NCT04204928","title":"Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT02174679","title":"68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT03906331","title":"Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Eli Lilly and Company","has_results":false}],"total":31},"guidelines":[],"source":"Drug Landscape verified database"}